NDUFS3
ENSG00000213619
Target class
Enzyme
Chromosome
11
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- ClinGen gene-disease validity
- Moderate
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Other names
- CI-30
- Target name
- NDUFS3
- Gene name
- NADH:ubiquinone oxidoreductase core subunit S3
- Gene symbol
- NDUFS3
- Protein name
- NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial (EC 7.1.1.2) (Complex I-30kD) (CI-30kD) (NADH-ubiquinone oxidoreductase 30 kDa subunit)
- Gene biotype
- Protein coding
- Gene family
- NADH:ubiquinone oxidoreductase core subunits
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 78.58
- Tissue specificity (Gini)
- 0.15
- Tissue specificity (tau)
- 0.419
- KEGG gene identifiers
- hsa:4722
- Protein interaction confidence
- 0.905295
- Protein interaction partners
- 155
- R-HSA-611105
- R-HSA-6799198
- R-HSA-9013408
- R-HSA-9837999
- End position
- 47584565
- Start position
- 47565336
- Chromosome
- 11
- Strand
- Forward
- Mitochondrion inner membrane
- Peripheral membrane protein
- Matrix side .
- Mitochondria
- PubMed 18826940
- PubMed 12611891
- PubMed 17209039
- Tissue specificity (tau)
- 0.418526
- Expression inequality (Gini)
- 0.150052
Expression in transcripts per million
- Muscle - Skeletal
- 78.58
- Brain - Cerebellar Hemisphere
- 77.67
- Brain - Caudate (basal ganglia)
- 72.34
- Brain - Putamen (basal ganglia)
- 68.79
- Brain - Frontal Cortex (BA9)
- 68.7
Expression in transcripts per million
- Muscle - Skeletal78.58
- Brain - Cerebellar Hemisphere77.67
- Brain - Caudate (basal ganglia)72.34
- Brain - Putamen (basal ganglia)68.79
- Brain - Frontal Cortex (BA9)68.7
- Brain - Cerebellum67.62
- Cells - EBV-transformed lymphocytes62.55
- Heart - Left Ventricle61.72
- Brain - Nucleus accumbens (basal ganglia)60.08
- Kidney - Medulla57.11
- Colon - Transverse55.91
- Adrenal Gland54.85
- Brain - Cortex54.53
- Pituitary54.46
- Brain - Anterior cingulate cortex (BA24)51.39
- Colon - Sigmoid50.08
- Brain - Hypothalamus49.41
- Cells - Cultured fibroblasts49.04
- Testis48.64
- Thyroid47.39
- Brain - Substantia nigra47.13
- Small Intestine - Terminal Ileum46.96
- Esophagus - Mucosa46.51
- Skin - Sun Exposed (Lower leg)44.67
- Spleen43.91
And 29 more, listed on the interactive page.
- GO:0006120
- GO:0021762
- GO:0032981
- GO:0072593
- GO:0005739
- GO:0005743
- GO:0005759
- GO:0031966
- GO:0045271
- GO:0003954
- GO:0005515
- GO:0008137
Related records
Trials (2,107)
- "Hepatic Substrate Flux Rates in Type 2 Diabetes"
- "MetCool ACS"- Metformin "Cooling" Effect on Metformin-naive Patients Treated With PCI Because of Acute Coronary Syndrome
- 1% Metformin Gel in the Treatment of Class II Furcation Defects
- 1% Metformin in Moderate and Severe Periodontitis
- 12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
- 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
- 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
- 30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
- 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
- A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
- A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers
- A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration
Drugs (4)
- ME-344 Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin hydrochloride Mitochondrial complex I (NADH dehydrogenase) inhibitor
- NV-128 Mitochondrial complex I (NADH dehydrogenase) inhibitor